ISIrina B. Semenova

Irina B. Semenova

*This is an algorithmically generated author record based on publicly available information.

Irina B. Semenova has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The effectiveness of SARS-CoV-2 infection emergency prevention with the immunostimulating antigens complex of opportunistic pathogenic bacteria

    by Oxana A. Svitich, Vitaly V. Zverev, Irina A. Leneva, Natalia A. Mikhailova, Anna V. Ivanina, Evgeny B. Faizuloev, Anastasiia V. Gracheva, Ekaterina R. Korchevaya, Alena V. Soldatenkova, Mikhail P. Kostinov, et al.

    COVID-19 pandemic has caused the deaths of more than 7 million people worldwide and revealed the weakness of the global health system in the face of such challenges. In conditions of low effectiveness for disease specific prevention, an important task is to develop drugs acting to stimulate innate immunity for emergency non-specific prevention of coronavirus diseases. The aim of the study was to evaluate the effectiveness of preventive administration of an immunostimulating drug based on antigens complex of opportunistic bacteria (ACOPB, the drug Immunovac-VP-4) in protecting against SARS-CoV-2 infection. Coronavirus pneumonia was modeled by infecting golden Syrian hamsters with the Wuhan-like SARS-CoV-2 Dubrovka strain, assessing indicators such as weight dynamics, viral load and pathomorphological changes in the lungs. Preventive administration of ACOPB to hamsters in the form of a spray and by inhalation helped protect them from SARS-CoV-2 infection and its pathogenic effects. The efficacy of the drug was manifested in protecting hamsters from weight loss, a decrease in viral reproduction in the lungs and the absence of pathological morphology changes in lung tissue. Thus, animals treated with ACOPB in the form of a spray or by inhalation on day 3 post-infection gained weight, average of 4.2±3.0% (p 0.05) and 8.8±1.3% (p 0.001), while the animals of the viral control lost 5.6±2.8% weight. The use of ACOPB reduced virus titer in the lungs of animals by more than 2.5 lg. In addition, in patients with moderate COVID-19, the clinical effect and effect of ACOPB on the level of secretory immunoglobulin A (sIgA) in the upper respiratory tract were studied. The use of ACOPB as part of the complex therapy of patients with COVID-19 was associated with increased sIgA level in the nasal and pharyngeal areas of the upper respiratory tract from day 1 to day 30 follow-up as well as improved patient clinical condition. Thus, the mucosal immunity formed with the use of ACOPB suppresses virus reproduction in the lungs and promotes recovery of COVID-19 patients. The results showed that the ACOPB is of interest for further research as a means of emergency prevention and treatment in new coronavirus infection.

  • Open Access

    Impairment of influenza A virus reproduction in vivo with siRNA-induced silencing of the NXF1, PRPS1 and NAA10 cellular genes

    by Evgenij A. Pashkov, George A. Pashkov, Firaya G. Nagieva, Alena A. Murzina, Irina B. Semenova, Galina N. Usatova, Oxana A. Svitich, Vitaliy V. Zverev

    Introduction. Among infectious lesions of the upper respiratory tract and lungs, the leading positions are occupied by infections associated with the influenza A virus. The currently used means of prevention and therapy cannot completely prevent the spread of influenza among the population; therefore, it is necessary to search for fundamentally new approaches, the use of which will overcome the problem of high morbidity and drug resistance. Currently, the phenomenon of RNA interference (RNAi) is increasingly establishing itself as a powerful tool in the suppression of viral reproduction. Previously, it was believed that viral genes serve as a classic target for RNAi, however, given the high variability of the influenza A virus and its drug resistance, it is more logical to shift the focus to the use of host cellular factors necessary for viral reproduction as targets. This approach will have a number of advantages, such as multidirectionality against a wide range of taxonomic groups of viruses whose reproduction mechanism may be similar, rapid design of similar compounds against "emergent" viruses, as well as synergy with other antiviral agents. The aim is to evaluate the anti-influenza effect of siRNAs targeting the NXF1, PRPS1 and NAA10 cellular genes in an in vivo model. Materials and methods. The influenza A/California/7/09 (H1N1)pdm09 virus strain adapted to Balb/c laboratory mice, as well as the L929 and MDCK cell cultures, were used. The study was carried out using biological (infection of laboratory animals), molecular genetic (transfection, nucleic acid isolation, real-time polymerase chain reaction with reverse transcription) and virological methods (titration by visual cytopathic effect, assessment of viral titer using the Ramakrishnan method). Results. It was shown that siRNAs targeting the NXF1, PRPS1 and NAA10 cellular genes, when used prophylactically in an in vivo model at a concentration of 1.5 nmol/μL, during infection with influenza virus strains A/California/7/09 (H1N1), at mouse semi-lethal doses (LD50), reduce viral replication to a level of 3.1 log10 TCID50/mL of cell medium, the amount of vRNA — to 3.2 log10 compared to the groups of non-specific and viral controls. Conclusions. A decrease in the expression of the NXF1, PRPS1 and NAA10 genes leads to a disruption of the life cycle and activity of influenza viruses. This approach can potentially be studied and used for closely and distantly related representatives of other virus families.

  • Immunological features of sepsis phenotypes and endotypes

    by M. B. Potapova, V. V. Zverev, M. A. Babaev, E. A. Bogdanova, O. O. Grin, I. B. Semenova, E. A. Meremianina, O. A. Svitich

    Sepsis is a heterogeneous and life-threatening condition caused by a dysregulated immune response to infection. The most severe form of sepsis is septic shock, characterized by arterial hypotension, impaired tissue perfusion, and hypoxia. Despite new findings in antimicrobial and intensive care therapy, the incidence and mortality rates of sepsis remain high, which underscores the relevance of further studies on its pathogenesis. In recent years, the research has shifted from clinical signs to analysis of immunological and molecular mechanisms, which allowed to identify specific phenotypes and endotypes of the disease. Sepsis phenotypes are based on clinical manifestations and biomarkers, whereas its endotypes are defined by molecular mechanisms, including immune gene expression patterns. This article reviews key aspects of the innate and adaptive immune responses in sepsis, including activation of proinflammatory cytokines, development of coagulopathies, deterioration of endothelial integrity and microvascular regulation. Moreover, the potential mechanisms, e.g., hyperinflammation, simultaneous development of immunosuppression, and functional exhaustion of immunocompetent cells are highlighted. Thus, immunological biomarkers are considered a promising tool for patient‘s stratification, prognosis prediction and personalized therapy. Current immunodiagnostic methods are also discussed in this article, including quantitative analysis of cytokine levels and assessment of innate immune dysfunction markers. Hence, current understanding of sepsis as an immunologically heterogeneous syndrome enables researchers to expand existing concepts of its pathogenesis. In contrast to classical concept based on a shift from inflammation to immune suppression, the novel results suggest a simultaneous presence of both processes in the same patient, making it necessary to reconsider the existing diagnostic and therapeutic approaches.


  • Antitumor effects of small interfering RNAs

    by E. A. Pashkov, A. A. Murzina, I. B. Semenova, M. N. Shatokhin, O. A. Svitich, V. V. Zverev

    The aim of our work was to summarize the existing results in anticancer therapy with small interfering RNAs (siRNAs), as well as to highlight the role of siRNA as a remodulator of the immune response in oncological diseases. The literature review includes an analysis of research publications from the PubMed, Embase, eLIBRARY, CyberLeninka and Web of Science, CNKI and MEDLINE databases. Sufficient challenges in cancer treatment occur due to the immune tolerance of tumors, their drug resistance, and a number of limitations in usage of conventional treatment schedules. The novel RNA interference (RNAi)-based approaches, may be implemented using small interfering RNA (siRNA) molecules. These methods may offer promising therapeutic strategies that will promote an immunomodulatory effect and targeted suppression of gene expression important for tumor growth. Inhibition of tumor regulatory pathways will affect tumor proliferation and metastasis, while mobilizing antitumor immunity through stimulation of Toll-like receptors, maturation of dendritic cells, and infiltration of cytotoxic T lymphocytes into the tumor. The in vivo studies of this approach in experimental models showed a decrease in the volume of melanoma, breast tumors and hepatocellular carcinoma up to 5 times, suppression of metastasis and increased overall survival. Cancer treatment is among the most significant problems of modern medicine, characterized by high mortality, mechanisms of immune tolerance and frequent emergence of resistance to existing therapeutic approaches. Despite the progress in modern oncoimmunology, usage of checkpoint inhibitors and targeted antitumor agents, the effectiveness of current approaches is limited by immunosuppressive microenvironment of tumors, heterogeneity of malignant cells, adverse effects and toxicity of the drug therapy. RNAi treatment is a promising approach that can simultaneously solve several key problems of oncoimmunology, such as suppression of the driver oncogenes; blocking tumor signaling pathways; as well as activation of innate immunity. The dual effect of RNAi, which consists of a direct effect on tumor cells and immune modulation of the tumor environment, makes RNAi an excellent tool for overcoming tumor immunotolerance and providing a direct cytotoxic antitumor effect.

  • Open Access

    Neutralizing ability of monoclonal antibodies directed to epitopes of functionally significant Streptococcus pneumoniae pneumolysin domain

    by Ekaterina A. Kurbatova, Irina V. Yakovleva, Natalya F. Gavrilova, Denis S. Vorobyev, Ekaterina E. Petukhova, Irina B. Semenova, Anton E. Zaitsev, Yuri V. Volokh, Nune O. Vartanova, Alexander V. Poddubikov, et al.

    Background. Pneumolysin (Ply) – bacterial cholesterol-dependent cytolysin produced by almost all strains of Streptococcus pneumoniae. Antibodies induced to pneumolysin for some extend are able to neutralize its pathogenic effect on cells.Aim. Investigation of the effect of monoclonal antibodies obtained to native (nPly) and recombinant (rPly) forms of Ply on the neutralization of the cytolytic activity of bacterial Ply in vitro and their preventive properties on mice challenged with a virulent strain of S. pneumoniae.Materials and methods. mAbs to the nPly and rPly forms of Ply was obtained from the ascitic fluid of mice. Polyclonal antibodies pAbs (rPly) were obtained from the serum of rabbits immunized with rPly. The inhibition of erythrocyte hemolysis was assessed by the minimum concentration of mAbs (nPly), pAbs (rPly) and pAbs (rPly), which prevents lysis of erythrocytes induced by nPly. The neutralizing ability of antibodies was evaluated on the ovarian cells of the Chinese hamster CHO-K1 by the minimum concentration of antibodies necessary to protect cells from 4 cytopathogenic doses of nPly. The protective properties of the antibodies were studied with a single intraperitoneal injection of 200 µg of antibodies to mice, followed by challenge with a lethal dose of S. pneumoniae.Results. It was shown that 24 hours after intraperitoneal administration of nPly to mice, the body weight of the animals decreased and degenerative forms of red blood cells appeared in the blood. In in vitro experiments, nPly caused hemolysis of erythrocytes and destruction of CHO-K1 cells by the mechanism of apoptosis. mAbs (nPly), mAbs (rPly) and pAbs (rPly) inhibited erythrocyte hemolysis and neutralized the destruction of CHO-K1 cells. The highest neutralizing activity was shown by mAbs (rPly) and pAbs (rPly). A single injection of the studied antibodies to mice caused a decrease of their death when infected with the S. pneumoniae strain. There were no differences in the protective activity of antibodies.Conclusion. Methods based on neutralizing the toxic effect of Ply S. pneumoniae with the help of antibodies can be considered as a tool to reduce the pathogenicity of pneumococci.


  • Open Access

    Cytopathogenic effect of Streptococcus pneumoniae native pneumolysin in CHO-K1 cells

    by E. A. Kurbatova, I. V. Yakovleva, N. F. Gavrilova, E. S. Petukhova, I. B. Semenova, A. E. Zaitsev, Yu. V. Volokh, A. Yu. Leonova, A. V. Poddubikov

    Background. Streptococcus pneumoniae (S. pneumoniae, pneumococci) is an opportunistic bacterium that causes inflammatory diseases in humans. One of the virulence factors of S. pneumoniae is pneumolysin (Ply), a cholesterol-dependent hemolytic toxin that interacts with cholesterol in eukaryotic cell membranes, forms pores and leads to cell destruction and death.Aim. Immunochemical characteristics of pneumolysin and evaluation of its cytotoxic effect in the culture of Chinese hamster ovarian cells CHO-K1.Materials and methods. To obtain Ply, the S. pneumoniae serotype 3 strain was cultivated in brain heart broth, bacterial cells were pelleted by centrifugation and subjected to ultrasonic disintegration. The presence of pneumolysin in the resulting preparation was confirmed by immunoblotting with monoclonal antibodies to recombinant pneumolysin. The cytopathogenic effect of Ply was studied in a culture of proline-dependent epithelial-like Chinese hamster ovary cells CHO-K1 in RPMI-1640 medium. The hemolytic activity of Ply was assessed in a reaction with mouse erythrocytes.Results. Using ultrasonic disintegration of cells of the S. pneumoniae serotype 3 strain followed by precipitation with ammonium sulfate, a protein that formed a band on electrophoresis at a level corresponding to the molecular weight of Ply (53 kDa) was obtained. The protein possessed the ability to lyse mouse erythrocytes. The authenticity of Ply was confirmed by immunoblotting with monoclonal antibodies to recombinant pneumolysin. Ply had a cytopathogenic effect on Chinese hamster ovary CHO-K1 cells. The minimum dose of the protein that induced a toxic effect on cells, manifested in the appearance of round and small cells along with normal cells, was 16.4 μg/ml per protein. When the concentration was increased up to 65.6 μg/ml, only small round cells were detected. Further increase in concentration resulted in complete destruction of CHO-K1 cells.Conclusion. Pneumolysin can be used to develop new drugs for the treatment of pneumococcal infections.


  • Open Access

    Development of the test system based on enzyme immunoassay for the detection of recombinant Streptococcus pneumoniae pneumolysin

    by E. A. Kurbatova, I. V. Yakovleva, N. F. Gavrilova, D. S. Vorobyev, E. S. Petukhova, I. B. Semenova, A. E. Zaitsev, Yu. V. Volokh, A. Yu. Leonova, A. V. Poddubikov, et al.

    Backgraund. Pneumolysin (Ply) is a hemolytic toxin of Streptococcus pneumoniae (S. pneumoniae) expressed by all strains of pneumococci. The use of sandwich enzyme-linked immunosorbent assay (ELISA) can be a simple, fast and effective way of its qualitative and quantitative determination in biological fluids.Aim. To develop and evaluate the specificity of sandwich ELISA test system for qualitative and quantitative determination of recombinant Ply (rPly) of S. pneumoniae.Materials and methods. Immobilized on the solid phase rabbit’s polyclonal antibodies (pAbs) to rPly were used as recognition antibodies in sandwich ELISA. The studied antigens were added to the pAbs (rPly). The reaction was manifested by using detecting mouse monoclonal IgG1 (rPly) – antibodies conjugated with horseradish root peroxidase. The specificity of the test system was evaluated when using recombinant α-hemolysin (rα-Hly) and water-soluble S. aureus antigens as reference preparations.Results. Using sandwich ELISA, rPly was detected at a concentration of 0.15 µ / ml. The test system was characterized by specificity, which was confirmed by the absence of reaction with recombinant rα-Hly of Staphylococcus aureus (S. aureus). Reference preparations of water-soluble surface antigens of S. aureus strains No 209, 1986,1991 and Cowan I gave a false positive reaction due to the presence of protein A (SpA) in their composition, a thermostable surface protein expressed by many strains of staphylococci capable of binding immunoglobulins via Fc-fragment or Fab fragments of the V3H domain of the B cells receptor. A negative reaction was obtained with antigens from the S. aureus wood 46 strain, which does not have the spa gene encoding SpA expression. The presence of protein A in preparations of water-soluble S. aureus antigens was confirmed in the ELISA inhibition assay.Conclusion. Sandwich ELISA has been developed for qualitative and quantitative determination of S. pneumoniae Ply. The conducted studies have confirmed the specificity of the test system.


  • Open Access

    Serotype-independent protective activity of recombinant pneumolysin in a model of systemic infection caused by Streptococcus pneumoniae serotypes 4 and 6B

    by D. S. Vorobyev, E. S. Petukhova, Yu. V. Volokh, O. М. Afanasyeva, M. M. Tokarskaya, A. Yu. Leonova, O. V. Zhigunova, I. B. Semenova, N. F. Gavrilova, I. V. Yakovleva, et al.

    Background. The development of a pneumococcal vaccine with serotype-independent activity is relevant for the whole world, as this is due to the high prevalence of Streptococcus pneumoniae (S. pneumoniae), the constant change of pathogen serotypes and the growth of antibiotic-resistant strains. In previous experiments, we revealed a protective effect of immunization with recombinant pneumolysin (rPly) in a model of systemic infection caused by S. pneumoniae serotype 3.Aim. Study of serotype-independent protective activity of rPly.Materials and methods. Strains of S. pneumoniae serotypes 4 and 6B were used. Mice were immunized intraperi-toneally two or three times with an interval of 14 days with rPly. To assess the protective activity of rPly, animals after double or triple immunization were infected intraperitoneally with S. pneumoniae .Results. rPly at a triple immunization in a dose of 25 μg protected mice from intraperitoneal infection with S. pneu- moniae serotype 4, the efficiency index increased by 2 times compared with the control. with a double immunization, rPly protected mice from intraperitoneal infection with S. pneumoniae serotype 6B, efficiency index increased by 6.61 times compared with the control.Conclusion. rPly protects animals from infection with different serotypes of S. pneumoniae, which allows us to consider it a promising drug for the development of pneumococcal vaccines with serotype-independent activity.

  • Open Access

    Protective activity of mixtures of pneumococcal antigens in infection caused by Streptococcus pneumoniae serotype 3

    by D. S. Vorobyev, M. M. Tokarskaya, S. A. Baranovskaya, E. A. Stefutushkina, O. M. Afanasyeva, E. A. Astashkina, O. V. Zhigunova, Yu. V. Volokh, A. Yu. Leonova, E. S. Petukhova, et al.

    Introduction. Pneumococcal diseases remain relevant for the whole world. On the one hand, this is due to the high prevalence of pneumococcus and the other hand, the growth of antibiotic-resistant strains and the constant change of clinically significant serotypes of the pathogen.The aim of the research was to study of the protective activity of a mixture of pneumococcal antigens.Material and methods. we used preparations of a capsular polysaccharide (CPS) obtained from Streptococcus pneumoniae serotype 3; protein-containing fraction (PCF) obtained from an aqueous extract of cells of S. pneumoniae serotype 6B; recombinant pneumolysin (rPly). Mice were immunized intraperitoneally twice with an interval of 14 days with mixtures of bacterial antigens: CPS + PCF; CPS + rPly; PCF + rPly. To assess the protective activity of the studied drugs after double immunization animals were infected intraperitoneally with S. pneumoniae serotype 3. To study the effect of mixtures of bacterial preparations on the infectious process in the lungs immunized mice were infected with S. pneumoniae serotype 3. The humoral immune response was studied with IgG using the method of ELISA.Results. The CPS + rPly mixture protected mice from intraperitoneal infection with S. pneumoniae serotype 3 regardless of the infecting dose. Immunization with CPS + PCF or CPS + rPly mixtures influenced a significant decrease the number of seeded bacterial cells from lungs during the entire observation period (72 h) compared to the control. Administration of mixtures of bacterial antigens of CPS + PCF, CPS + rPly or PCF + rPly to animals led to a significant increase of the level of antibodies to all antigens, however, the highest levels of IgG were determined to PCF and rPly.Conclusion. The results obtained suggest that different antigenic drugs in mixtures affect different mechanisms of immunity activation.